[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Carilion Clinic\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":222},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,73,112,141,169,194],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100643915","modi-twin-placental-imaging-100643915",false,"NCT07667647","MoDi Twin Placental Imaging","Healthy Monochorionic Diamniotic Twin Microvasculature and Placental Imaging","Inclusion Criteria:\n\n1. Subject is 18 to 45 years of age at screening\n2. Non-anomalous, monochorionic, diamniotic (MoDi) or monochorionic, monoamniotic (MoMo) twin gestation without suspected genetic disorders\n3. Low-risk aneuploidy screening, if performed\n4. Intention to deliver at Carilion Roanoke Memorial Hospital (CRMH) or Carilion New River Valley Medical Center (CNRVMC)\n5. Anatomical survey has been performed\n6. 18 - 26 weeks gestational age\n\n8\\. Subject willing and able to provide\u002Fre-provide informed consent\n\nExclusion Criteria:\n\n1. Suspected fetal genetic disorder(s)\n2. Suspected fetal infection(s), twin-twin transfusion syndrome (TTTS), twin reversed arterial perfusion sequence (TRAPS), or maternal vascular disease\n3. Non-English reading and speaking\n4. Unstable housing or transportation\n5. Any other criterion which, in the clinical judgement of the investigator, would make the subject unsuitable for study enrollment","FEMALE","18 Years","45 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","Twin-twin transfusion syndrome (TTTS) can arise in monochorionic, diamniotic (MoDi), those identical twins arising from division of a single fertilized ovum at 4-8 days gestational age (GA) or monochorionic, monoamniotic (MoMo or Mono-Mono) twins, arising from division on day 8-13 GA.\n\nIn monochorionic twin pregnancies sharing a single placenta often unevenly, anastomoses \\[connections\\] artery to artery (AA), vein to vein (VV), and artery to vein (AV) can occur.\n\nAV anastomoses usually flow unilaterally, shunting blood unevenly towards one twin and away from the other. This can lead to fluid overload and polyhydramnios along with many other pathologies in one twin while the other twin suffers from inadequate blood flow and oligohydramnios, along with secondary pathologies arising from these conditions.\n\nTTTS will affect approximately 8-10% of MoDi twins while 6% of MoMo twins will suffer with this condition.\n\nTreatment for TTTS is necessary, with the donor or 'pump' twin having around an 80% chance of death without medical intervention.\n\nThe aim of this single arm, unblinded, feasibility study of the Verasonics Vantage 256 device is to leverage the devices ultrafast power Doppler imaging (uPDI) to perform microvascular mapping of the placenta in healthy, non-anomalous, 18-26 week gestational age (GA), monochorionic, diamniotic (MoDi) or monochorionic, monoamniotic (MoMo\u002FMonoMono) pregnancies without TTTS, twin reversed arterial perfusion sequence (TRAP), or maternal vascular disease.\n\nParticipants will be recruited in the Maternal Fetal Medicine department of Carilion Clinic, which specializes in high risk or complicated pregnancies. Pregnant subjects carrying monochorionic twins and scheduled for appointments at the clinic, who meet study eligibility criteria, will be approached between weeks 18 and 26 for study enrollment.\n\nThose providing informed consent will undergo a single, transabdominal ultrasound examination by a licensed ultrasonographer or obstetrician with the Verasonics Vantage 256 ultrasound machine, with imaging focused on mapping the vasculature of the placenta with ultrafast power Doppler imaging (uPDI). The ultrasound exam will last about 15 minutes and occur immediately after the subject's standard-of-care appointment at the clinic so as not to inconvenience subjects more than necessary. Similar to commercially marketable ultrasounds in the US, the Verasonics ultrasound will use the principle of 'As Low As Reasonably Achievable (ALARA) to output the lowest acoustic waves possible to achieve the ultrasound imaging.\n\nAfter the single ultrasound scan, subjects' electronic medical records will be used to source demographic, medical, obstetric, and other historical datapoints to better characterize the 10-subject study population and their babies.\n\nNo follow-up contact with subjects is expected after the single research ultrasound visit.",[27,28,29,30,31,32,33,34],"Monochorionic Diamniotic Placenta","Monochorial Monoamniotic Placenta","Monochorionic Twins","Ultrasound Doppler","Ultrasound","Pregnancy","Twin Pregnancy, Monochorionic","Twin Twin Transfusion Syndrome",[36,37,38,39,40,32,41,42,43,44,45,46,47,48,49,50,34,51,52,53,54,55,56,57,31,58,59,60],"Carilion Clinic","Maternal Fetal Medicine","Obstetrics","OB","OBGYN","Twin Pregnancy","Whitham","Monochorionic","Monochorionic Diamniotic","MoDi","MoMo","Monochorionic Monoamniotic","Twin","TTTS","Twin-Twin Transfusion Syndrome","uPDI","ultrafast power Doppler Imagine","Quantitative Ultrasound","QUS","Fetoscopic laser photocoagulation","FLP","Verasonic","Doppler","Doppler Imaging","Prenatal Care","NOT_YET_RECRUITING","2026-06-19",{"date":64,"type":65},"2026-06-25","ACTUAL",{"date":67,"type":21},"2026-07-01",{"date":69,"type":21},"2029-07-01",{"name":36,"class":71},"OTHER",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":91,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":72},"100582284","placental-imaging-techniques-100582284","NCT06861309","Placental Imaging Techniques","Evaluation of Innovative Placental Imaging Techniques in Fetal Growth Restriction","Inclusion Criteria:\n\n* Normal-Fetal-Weight Pregnancies Arm: Patient at least 18 to 45 years of age at screening\n* Normal-Fetal-Weight Pregnancies Arm: Non-anomalous, singleton gestation without suspected genetic disorders or growth abnormalities\n* Normal-Fetal-Weight Pregnancies Arm: Low-risk aneuploidy screening, if performed\n* Normal-Fetal-Weight Pregnancies Arm: Intention to deliver at Carilion Roanoke Memorial Hospital (CRMH) or Carilion New River Valley Medical Center (CNRVMC)\n* Normal-Fetal-Weight Pregnancies Arm: Anatomical survey has been performed\n* Normal-Fetal-Weight Pregnancies Arm: Pregnancy without current fetal growth restriction (FGR) diagnosis\n* Normal-Fetal-Weight Pregnancies Arm: Subject willing and able to provide informed consent Note: Verify that the most recent version of the ICF was used to consent the subject\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Patient at least 18 to 45 years of age at screening\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Non-anomalous, singleton gestation without suspected genetic disorders\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Low-risk aneuploidy screening, if performed\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Intention to deliver at Carilion Roanoke Memorial Hospital (CRMH) or Carilion New River Valley Medical Center (CNRVMC)\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Anatomical survey has been performed\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Pregnancy diagnosed with fetal growth restriction (FGR) by estimated fetal weight \\\u003C10th centile or abdominal circumference measurements \\\u003C10th centile\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Subject willing and able to provide informed consent Note: Verify that the most recent version of the ICF was used to consent the subject\n\nExclusion Criteria:\n\n* Normal-Fetal-Weight Pregnancies Arm: Multiple gestations\n* Normal-Fetal-Weight Pregnancies Arm: Known fetal anomaly affecting biometric measurements\n* Normal-Fetal-Weight Pregnancies Arm: Suspected fetal genetic disorder(s)\n* Normal-Fetal-Weight Pregnancies Arm: Suspected fetal infection(s)\n* Normal-Fetal-Weight Pregnancies Arm: Non-English or Spanish-speaking\n* Normal-Fetal-Weight Pregnancies Arm: Unstable housing or transportation\n* Normal-Fetal-Weight Pregnancies Arm: Any other criterion which, in the clinical judgement of the investigator, would make the subject unsuitable for study enrollment.\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Multiple gestations\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Known fetal anomaly affecting biometric measurements\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Suspected fetal genetic disorder(s)\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Suspected fetal infection(s)\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Non-English or Spanish-speaking\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Unstable housing or transportation\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Any other criterion which, in the clinical judgement of the investigator, would make the subject unsuitable for study enrollment.",{"count":81,"type":21},60,[24],"The goal of this proof-of-concept, case-control, clinical trial is to evaluate the efficacy of using two newer ultrasound technologies, quantitative ultrasound (QUS) and ultrafast power Doppler imaging (uPDI), to evaluate the health of the placenta, visualize blood flow through the placental vasculature by color Doppler imaging in singleton pregnancies with and without fetal growth restriction (FGR).\n\n* Our primary objective is to investigate the ability of using these ultrasound technologies to distinguish healthy pregnancies from those affected by FGR, a condition characterized by a fetal weight below the 10th percentile for the gestational age or abdominal circumference of the pregnancy.\n* Secondary aims include longitudinal evaluation of differences in QUS and uPDI imaging over gestation and changes in these measures with evolution of utero-placental insufficiency including with the development of abnormal umbilical-artery Doppler testing, diagnosis of severe FGR, identification of stillbirth, and detection of preeclampsia or preterm birth.\n\nInvestigators will compare QUS\u002FuPDI imaging and values in pregnancies determined to be healthy by approved, standard-of-care growth ultrasounds to those diagnosed with FGR.\n\nParticipants will receive research ultrasounds with the experimental Verasonics Vantage 256 system (Verasonics, Inc, Kirkland, WA) utilizing uPDI\u002FQUS every three weeks following their routine growth ultrasound evaluation until delivery. Demographic, obstetric, and delivery-related information, as well as portions of subjects' past medical history will be utilized by researchers to further contextualize imaging and variables gathered during the research ultrasounds.",[85,86,87,88,32,89,90,31],"Fetal Growth Restriction (FGR)","Placental Insufficiency","Preeclampsia","Still Births","Pregnancy Complications","Pregnancy Outcomes",[92,93,94,95,96,31,32,89,37,97,53,51,54,98,99,87,100,101,36,102],"Fetal Growth Restriction","FGR","Placental Imaging","Utero-Placental Insufficiency","Growth Restriction","Ultrafast Power Doppler Imaging","MFM","Stillbirth","Verasonics","Verasonics Vantage 256","Virginia Tech","RECRUITING","2026-05-20",{"date":106,"type":65},"2026-05-22",{"date":108,"type":65},"2025-04-23",{"date":110,"type":21},"2026-11",{"name":36,"class":71},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":119,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":126,"conditions":127,"keywords":131,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":72},"100612982","early-phase-1-efficacy-of-a-topical-palmitated-formulation-of-capsaicin-capsadyn-in-the-treatment-of-diabetic-neuropathic-foot-pain-100612982","NCT07260656","Efficacy of a Topical Palmitated Formulation of Capsaicin (Capsadyn®) In the Treatment of Diabetic Neuropathic Foot Pain","A Double-Blind, Randomized, Pilot Study to Investigate the Efficacy of a Topical Palmitated Formulation of Capsaicin (Capsadyn®) In the Treatment of Diabetic Neuropathic Foot Pain","Inclusion Criteria:\n\n* At least 3 toes per foot\n* Have otherwise intact feet.\n* Absence of any eczema, hyperkeratosis, scleroderma, or other dermatological conditions afflicting the area of Test Article administration that may interfere with absorption, particularly hyperhidrosis.\n* Must agree to apply the Test Article to painful areas of feet as directed by research personnel.\n* Must agree to apply the Test Article to feet as instructed 2x per day.\n* Must wait 60 minutes after each application of Test Article before filling out NRS forms.\n* Unless burning is encountered soon after application, the participant must wait at least 60 minutes before washing feet after application of Test Article.\n* All participants must be willing to use Test Articles blinded.\n\nExclusion Criteria:\n\n* Younger than 25 and older than 75 years of age\n* Any dermatological condition(s) with the potential to disrupt skin integrity or alter sensory function of the feet.\n* Any open wounds, skin ulceration, infection, skin irritation (e.g., poison oak), history of eczema, trauma or burn (including sunburn) affecting the feet within 30 days.\n* Any recent medical history of surgery affecting the feet.\n* Unless part of a stable continuum of substance use prior to start of study, the use of any topical medication products on feet, including holistic formulations, patch or herbal products, cannabinoid products, prescription or over the-counter (OTC) analgesic creams\u002Flotions\u002Fpatches\u002Fgels, nonsteroidal anti-inflammatory drugs, acetaminophen, counterirritants, local anesthetics, or steroids is prohibited.\n* Current substance abuse.\n* History of hypersensitivity or allergy to chili peppers, coconut oil, Shea butter, or sunflower seed oil.\n* Except for interventions for mobility, (e.g., physical therapy, exercise, grounding) no concurrent foot therapy for pain that may interfere with NRS evaluations is permitted (e.g., massage, electrophoresis, red light, etc.).\n* No concurrent enrollment in another clinical trial.","ALL","25 Years","75 Years",{"count":123,"type":21},80,[125],"EARLY_PHASE1","The purpose of this research is to assess whether the use of a topical cream with an active ingredient can reduce the amount of foot pain experienced in participants who have been diagnosed with Diabetic Peripheral Neuropathy (DPN) with minimal side effects or discomfort from use.",[128,129,130],"Diabetic Neuropathies, Painful","Diabetic Foot","Diabetic Peripheral Neuropathy",[132],"diabetic foot pain","2026-04-15",{"date":135,"type":65},"2026-04-20",{"date":137,"type":65},"2025-11-26",{"date":139,"type":21},"2027-11",{"name":36,"class":71},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":149,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":72},"100633465","phase-4-pectoral-block-in-breast-reduction-for-pain-control-100633465","NCT07527039","Pectoral Block in Breast Reduction for Pain Control","Intraoperative Pectoral Block in Breast Reductions: Reduction in Pain Scores & Elimination of Narcotic Use","Inclusion Criteria:\n\n* Undergoing breast reduction surgery\n* Women older than age 18 and under age 75\n* Stable breast size for at least 1 year\n* Member has persistent symptoms in at least two of the anatomical body areas below, directly attributed to macromastia and affecting daily activities for at least 1 year:\n\nHeadaches; Pain in neck; Pain in shoulders; Pain in upper back; Painful kyphosis documented by X-rays; Pain\u002Fdiscomfort\u002Fulceration from bra straps cutting into shoulders; Skin breakdown (severe soft tissue infection, tissue necrosis, ulceration hemorrhage) from overlying breast tissue; Upper extremity parasthesia\n\n* Patient has evidence of severe breast hypertrophy that is documented by frontal and side profile photographs\n* Pain symptoms persist as documented by the physician despite at least a 3-month trial of therapeutic measures such as:\n\nAnalgesic\u002Fnon-steroidal anti-inflammatory drugs (NSAIDs) interventions and\u002For muscle relaxants Dermatologic therapy of ulcers, necrosis and refractory infection Physical therapy\u002Fexercises\u002Fposturing maneuvers Supportive devices (e.g., proper bra support, wide bra straps) Chiropractic care or osteopathic manipulative treatment Medically supervised weight loss program Orthopedic or spine surgeon evaluation of spinal pain\n\n* Breast Reduction is likely to cause a reduction in patient symptoms\n* Women 50 years of age or older are required to have a mammogram that was negative for cancer performed within the two years prior to the date of the planned reduction mammoplasty\n* Greater than 40 kg in weight\n\nExclusion Criteria:\n\n* History of chronic pain controlled with prescribed narcotics\n* English as non-primary language\n* No access to email or internet\n* Positive pre-surgery pregnancy test\n* Women not of ages 18-75\n* Less than 40 kg in weight",{"count":123,"type":21},[150],"PHASE4","A reduction mammoplasty is a commonly performed procedure for patients with symptomatic macromastia. The procedure involves removing breast parenchyma for an overall reduction in breast size and to alleviate patient symptoms, such as back\u002Fneck pain, rashes in the inframammary fold, and bra strap indentation. It is well documented in the literature that this procedure has a statistically significant reduction in patient symptoms. Postoperatively, it has been within the norm to prescribe narcotics in order to alleviate post-procedural pain. Recently, however, the research realm has advocated a non-narcotic multimodal pain control (MMPC) approach to minimize narcotic usage. Narcotic use is associated with increased costs in the healthcare system due to reported heightened pain scores for extended duration, constipation, nausea, vomiting, opiate dependence among other factors associated with increased morbidity.\n\nThe goal of this study is to determine if PECs II (pectoral block type II) block alone is non-inferior to the standard multimodal pain control with narcotics for postoperative pain reduction in breast reduction.",[153],"Macromastia (Symptomatic)",[155,156,157,158,159,160],"Macromastia","Pectoral nerve block","PEC II block","Opioid reduction postoperatively","breast reduction","reduction mammaplasty","2026-04-08",{"date":163,"type":65},"2026-04-14",{"date":165,"type":65},"2026-04-01",{"date":167,"type":21},"2028-05",{"name":36,"class":71},{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":176,"sex":119,"minAge":17,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":180,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":72},"100539917","3d-printed-personalized-ostomy-appliance-100539917","NCT06310070","3D Printed Personalized Ostomy Appliance","3DPPOA","Inclusion Criteria:\n\n* 18-100 years old\n* Must have had current ostomy appliance for \\> 6 weeks - if patients with stomas less than 6 weeks are included, their personalized templates will not be useful once the stoma size has changed after their initial scan.\n* Must have experienced \\> 1 leakage in the week leading up to day of consent. - If patients are not experiencing leakages, then there will be no baseline data to compare effectiveness of the post-3D appliance intervention.\n* Participants must be able to consent for themselves\n* Access to phone AND computer with internet access. Patient must be able to provide electronic mailing address for e-consent documentation and REDCap surveys.\n\nExclusion Criteria:\n\n* Concern for patient being able to be reached over the phone or reliable internet access for REDCap survey completion\n* Existing peri-stomal skin breakdown including ulceration or mucocutaneous separation.\n* Diagnosis of infection around the peristomal region. (erythema is NOT an exclusion criteria)",true,"100 Years",{"count":179,"type":21},30,[24],"The goal of this clinical trial is to learn about the effectiveness of using a 3D scan for a personal ostomy appliance. The main question it aims to answer is:\n\n• Whether or not a 3D scan of a stoma reduces leakages and improves patient quality of life in regard to using a personalized ostomy appliance.\n\nParticipants will\n\n* Spend 2 weeks with their standard of care ostomy appliance\n* Spend 2 weeks with their personalized ostomy appliance made from a 3D scan\n* Participate in daily surveys and weekly quality of life surveys conducted over the phone",[183,184,185],"3D Printing","Ostomy","Leakage","2025-01-20",{"date":188,"type":65},"2025-01-22",{"date":190,"type":65},"2024-05-10",{"date":192,"type":21},"2025-06-05",{"name":36,"class":71},{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":119,"minAge":17,"maxAge":177,"enrollmentInfo":202,"targetDuration":4,"studyType":22,"phases":204,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":72},"100370996","rct-early-feeding-after-peg-placement-100370996","NCT04110613","RCT: Early Feeding After PEG Placement","A Randomized Controlled Trial to Reduce Periprocedural Fasting in Ventilated Trauma and Surgical Intensive Care Patients","PEG","Inclusion Criteria:\n\n* Adult subjects over 18 years of age\n* Negative pregnancy test for women participants of child-bearing age\n* Mechanically ventilated surgical and trauma patients with clinical indication for PEG tube placement\n* Tolerating tube feeds at goal prior to procedure\n\nExclusion Criteria:\n\n* Patients with aberant gastrointestinal anatomy\n* Patients with gastrointestinal motility disorders\n* Patients with feeding intolerance prior to PEG tube procedure\n* Pregnant women, children, or other vulnerable populations\n* Clinical contraindications for PEG tube placement\n* PEG performed in setting other than ICU at bedside",{"count":203,"type":21},1200,[24],"Randomized controlled trial to establish evidence on which to base timing of enteral feeding after bedside PEG placement in ventilated Trauma and Surgical ICU patients.",[207,208,209,210,211,212,213],"Critical Illness","Malnutrition","Gastrostomy","Procedural Sequelae","Trauma","Surgery","Mechanical Ventilation","2021-10-18",{"date":216,"type":65},"2021-10-26",{"date":218,"type":65},"2019-09-19",{"date":220,"type":21},"2026-09-30",{"name":36,"class":71},""]